• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Viloxazine for ADHD

Viloxazine for ADHD

November 5, 2021
Thomas Jordan, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Thomas Jordan, MD. Dr. Jordan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Nasser A et al, Int J Clin Pract 2021;75(8):e14330


Study type: Meta-analysis of randomized controlled trials


Viloxazine (Qelbree) just got FDA approval in 2021 for the treatment of ADHD in children and adolescents, and the FDA is reviewing data in adult ADHD. Viloxazine has a long history of use as an antidepressant in Europe. Like atomoxetine (Strattera), it is a selective norepinephrine reuptake inhibitor. Stimulants are still the most effective medications for ADHD, so how does this new nonstimulant option measure up? This meta-analysis offers a clue.


The analysis included four randomized, double-blind, placebo-controlled trials. When analyzed together, they showed viloxazine was more effective than placebo at reducing ADHD symptoms in a combined 1354 children and adolescents. On an individual level, three of the four trials were positive. All four trials used improvement in the ADHD Rating Scale (ADHD-RS) after five weeks of treatment as their primary outcome. There were two levels of improvement: a 30% improvement in ADHD-RS or a more clinically significant 50% improvement in ADHD-RS.


The authors then converted these results into more clinically relevant figures: number needed to treat (NNT) and number needed to harm (NNH). The NNT represents the number of patients a clinician would need to treat to have one positive response, after removing the placebo effect. NNH is the number a clinician would need to treat to cause harm to one patient (in this case, “harm” was defined as discontinuing the trial due to any adverse effect). An NNT under 10 is considered clinically meaningful, and an NNH over 10 is considered relatively safe or acceptable.


For these studies, the NNT was 6 (95% CI: 5–9) for the less stringent 30% improvement in ADHD-RS and 7 (95% CI: 5–10) for the 50% improvement level. The NNH was 46 (95% CI: 26–167), meaning one in 46 patients discontinued the medication due to side effects for both 30% and 50% levels of improvement. The most common side effects were somnolence, decreased appetite, and headache. By contrast, other analyses have found similar NNTs for atomoxetine (5–7) and better NNTs for traditional stimulants (2–4).


Two main weaknesses stand out. The analysis was industry sponsored and was a meta-analysis of four studies that were also industry sponsored. The other limitation is generalizability—children and adolescents with solely ADHD and no other significant mental or neurological disorder participated in these studies.


TCPR’s Take
In children and adolescents with ADHD, viloxazine is well tolerated with an efficacy comparable to atomoxetine but less than the stimulants. The medication is not approved in adult ADHD, but the company has submitted data for adults to the FDA that are currently under review.

General Psychiatry
KEYWORDS adhd atomoxetine attention-deficit-hyperactivity-disorder qelbree research-update viloxazine
    Thomas Jordan, MD.

    Methylphenidate Max Dosing

    More from this author
    www.thecarlatreport.com
    Issue Date: November 5, 2021
    SUBSCRIBE NOW
    Table Of Contents
    How to Treat ADHD in Bipolar Disorder
    In the News: Aducanumab (Aduhelm)
    Viloxazine for ADHD
    Listening to Depression: The Importance of Addressing Hearing Loss
    Establishing a Dose-Response Relationship for Lurasidone in Acute Schizophrenia
    Sleepwalking on Antipsychotics and Lithium
    In Brief: Meds in the Fast Lane
    How to Diagnose Bipolar Disorder
    Nutritional Psychiatry in Practice
    CME Post-Test - Bipolar Disorder, TCPR, November/December 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.